Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for prevention of doxorubicin cardiotoxicity in breast cancer
IRCT20231017059748N7Phase 3Recruiting
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Dapagliflozin placebo + doxorubicin with Dapagliflozin + doxorubicin (2 arms). Primary endpoints: Global longitudinal strain and N-terminal pro-B-type natriuretic peptide. Started Aug 2026; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20231017059748N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231017059748N7.